Goal #4: Improve clinical research

Returning genetic results to research participants requires thoughtful planning. ICTS Precision Health at Washington University in St. Louis aims to catalyze genomic research by providing grant review and development services, guidance and resources for genomic researchers and genomics education in the community. <a href="https://icts-precisionhealth.wustl.edu/" target="_blank" rel="noopener noreferrer">Precision Health</a> is a component of the <a href="https://icts.wustl.edu/about/structure/" target="_blank" rel="noopener noreferrer">Institute of Clinical and Translational Sciences</a>’ Clinical and Translational Science Award, granted by the National Center for Advancing Translational Sciences at the NIH…&nbsp;Read the full article <a href="https://icts.wustl.edu/icts-precision-health-team-develops-genomic-return-of-results-service/" target="_blank" rel="noopener noreferrer">here</a>.

Washington University in St. Louis Institute of Clinical and Translational Sciences

large_Wash Uni ICTS.png

medium_Wash Uni ICTS.png

small_Wash Uni ICTS.png

thumbnail_Wash Uni ICTS.png

Wash Uni ICTS.png

Washington University in St. Louis

ICTS Precision Health Team Develops Genomic Return of Results Service

- Any -

The <a href="https://covid.cd2h.org/cardiology" target="_blank" rel="noopener noreferrer">Cardiovascular Diseases Domain Team (CVDT)</a> is composed of individuals with a variety of backgrounds including clinicians, analysts, biostatisticians, and scientists from many institutions across the country, working collaboratively towards new discoveries of the impact of COVID-19 on cardiovascular diseases. Since the first meeting in February 2021, this group has been productive in researching COVID-19-related clinical cardiovascular health problems, learning about the relationship between COVID-19 and cardiovascular disease, and disseminating findings through manuscripts and abstract presentations at national meetings. In addition, CVDT members have been involved in supporting the N3C community in a number of activities including concept set creation and quality review of concept sets that have led to supporting the creation of N3C recommended concept sets and serving as beta-testers for the new publications intent platform. &nbsp;Early efforts by the CVDT focused on investigating the impact of COVID-19 on patients with active cancers and measuring differences in major adverse cardiovascular events (MACE). This work resulted in three abstract presentations at the American College of Cardiology (ACC) 2022 Annual Meeting (<a href="https://www.jacc.org/doi/10.1016/S0735-1097%2822%2903131-X" target="_blank" rel="noopener noreferrer">Patel B, et al</a>, <a href="https://www.jacc.org/doi/10.1016/S0735-1097%2822%2903087-X" target="_blank" rel="noopener noreferrer">Visaria A, et al</a>, <a href="https://www.jacc.org/doi/10.1016/S0735-1097%2822%2902941-2" target="_blank" rel="noopener noreferrer">Visaria A, et al</a>) and a recent publication in the journal Cardio-Oncology (<a href="https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs40959-023-00187-w%3Futm_source%3Drct_congratemailt%26utm_medium%3Demail%26utm_campaign%3Doa_20231006%26utm_content%3D10.1186%2Fs40959-023-00187-w&amp;data=05%7C01%7CTAYLOR.DUPREE%40cuanschutz.edu%7Cf950887115d1468ab72408dbd406b6d5%7C563337caa517421aaae01aa5b414fd7f%7C0%7C0%7C638336897539204642%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=URhAwq9py6usqw%2Ft4mUv3yZ0DP6AfXYn2Bj0zr2%2Bjjg%3D&amp;reserved=0" target="_blank" rel="noopener noreferrer">Patel B, et al.</a>). Additional work resulting in abstract presentations at ACC include an evaluation of outcomes and complications in patients with CVD infected with COVID-19 (<a href="https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.jacc.org%2Fdoi%2F10.1016%2FS0735-1097%252822%252903104-7&amp;data=05%7C01%7CTAYLOR.DUPREE%40cuanschutz.edu%7Cf950887115d1468ab72408dbd406b6d5%7C563337caa517421aaae01aa5b414fd7f%7C0%7C0%7C638336897539204642%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=VoDWHMVGbK25WEb7o0UKt1B%2FkXT3zmkFmWOlcnTxGic%3D&amp;reserved=0" target="_blank" rel="noopener noreferrer">Khodaverdi M, et al.</a>) and the impact of health disparities in vaccinated CVD patients infected with COVID-19 (<a href="https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.jacc.org%2Fdoi%2F10.1016%2FS0735-1097%252822%252903119-9&amp;data=05%7C01%7CTAYLOR.DUPREE%40cuanschutz.edu%7Cf950887115d1468ab72408dbd406b6d5%7C563337caa517421aaae01aa5b414fd7f%7C0%7C0%7C638336897539204642%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=uhVNl%2FmRR8JzOrMCG0okBTZNjkhczAOPWj6iQjnr66k%3D&amp;reserved=0" target="_blank" rel="noopener noreferrer">Khodaverdi M, et al</a>). &nbsp;More recent work has been related to exploring the impact of CVD-related comorbidities on MACE outcomes in COVID-19-infected patients with pre-existing heart failure (Jacob Neumann, project lead) and myocarditis/pericarditis diagnosis trends during the pre-COVID-19 era (Jan 2018-March 2020), the COVID-19/pre-vaccine era (April-December 2020), and COVID-19 and vaccine era (January 2021-March 2023). The CVDT has also explored the incidence of new cardiovascular complications between COVID-19 infection and receiving an mRNA vaccine (Scott Chapman and Sameh Hozayen, project leads). Findings from Selected Research Projects Includes:<ul><li><a href="https://pubmed.ncbi.nlm.nih.gov/37292998/" target="_blank" rel="noopener noreferrer">Outcomes of Patients with active cancers and pre-existing cardiovascular diseases infected with SARS-CoV-2</a><ul style="list-style-type:circle;"><li>We examined patients who were had a history of cardiovascular disease (CVD) who did or did not have active cancer (defined as last record of receiving a cancer treatment within 30 days of and the outcome of MACE were compared across 4 groups (CVD (-), CVD (+), Cardioonc (-) and Cardioonc (+). &nbsp;The research objective was to determine the impact of COVID-19 infection on patients with concomitant active cancers. &nbsp;Patients with both CVD and active cancer suffered relatively worse outcomes when they had acute COVID-19 infection during early and alpha surges in the United States. These findings highlight the need for improved management strategies and further research to better understand the impact of the virus on vulnerable populations during the COVID-19 pandemic.</li></ul></li></ul>&nbsp;<ul><li>COVID-19 Related Major Adverse Cardiovascular Events in Patients with Pre-Existing Heart Failure.<ul style="list-style-type:circle;"><li>Patients with heart failure are at increased risk for COVID-19 related complications. &nbsp;In this study, we evaluated patients with pre-existing heart failure and risk factors associated with MACE. &nbsp;COVID-19 infection resulted in increased risk of MACE in patients with underlying CV co-morbidities. Patients with prior kidney disease had increased risk of 90 day mortality.</li></ul></li></ul>&nbsp;<ul><li>Myocarditis and Pericarditis Diagnosis Trends from 2018-2023 and the Influence of COVID-19 Infection and mRNA COVID-19 Vaccines.<ul style="list-style-type:circle;"><li>Myocarditis and pericarditis diagnosis trends were explored from 2018-2023 to compare incidence during pre-COVID-19 era (Time 1: January 2018-March 2020), COVID-19 era without mRNA vaccine (Time 2: April -December 2020) and during COVID-19 era with mRNA vaccine (Time 3: January 2021-March 2023). &nbsp;We also sought to explore differences in the incidence across the 3 time periods between no COVID or vaccine, COVID-19, and mRNA vaccine. &nbsp;We found myocarditis and pericarditis increased during the COVID-19 pandemic relative to pre-pandemic levels (2.21 vs. 4.31 vs. 3.86 %/month/1000 patients for Time periods 1, 2, and 3, respectively), and was highest in those who did not have a COVID-19 infection or received an mRNA vaccine within 21 days of myo/pericarditis diagnosis (Time 2: 3.89; Time 3: 3.47) compared to COVID-19 infected patients (Time 2: 0.42, Time 3: 0.32), and lowest in the mRNA vaccine (Time 3: 0.056).</li></ul></li></ul>&nbsp;<ul><li>Comparison of Cardiovascular Complications Associated with Myocarditis and Pericarditis Between COVID-19 Infection and mRNA COVID-19 Vaccines.<ul style="list-style-type:circle;"><li>We evaluated myo/pericarditis incidence and compared new cardiovascular diagnoses and severity of illness between COVID-19 and mRNA vaccine patients with myo/pericarditis. &nbsp;Myo/pericarditis diagnosis was considerably more common in COVID-19 infection compared to mRNA vaccine (84.2% vs. 15.8%). &nbsp;There were more patients who had new heart failure diagnosis (29% vs. 24%), and cardiomyopathy (20% vs. 14%) with COVID-19 infection compared to mRNA vaccine recipients. &nbsp; Atrial arrhythmias were more common in mRNA vaccine (14% vs. 17%). Hospitalization was similar (54% vs. 52%) but severity of illness was more common in the COVID-19 cohort (25% vs. 12%).</li></ul></li></ul>&nbsp;<ul><li>Methodological Quality Checks for OMOP Drug Concept Set Creation; <a href="https://s4.goeshow.com/amia/annual/2023/schedule_at_a_glance.cfm?session_key=B915E0CE-DB7C-0649-CDD6-2667278FAF5C&amp;session_date=Monday,%20Nov%2013,%202023" target="_blank" rel="noopener noreferrer">Patel S et al.</a><ul style="list-style-type:circle;"><li>Quality of concept sets is a key aspect of the N3C and researcher reliability in the accuracy and intended reflection of the tools used by N3C researchers. &nbsp;CVDT members collaborated with members of the RECOVER Long COVID initiative to review and develop a framework for iterative quality checks and clinician verification within the OMOP CDM vasoactive agents concept set. &nbsp;This work will be presented at the upcoming AMIA Annual Symposium.</li></ul></li></ul>The CVDT welcomes new team members and project ideas and has offered collaborative support for new projects. To learn more about the Cardiovascular Diseases Domain Team or to join our Domain Team, please visit <a href="https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcovid.cd2h.org%2Fcardiology&amp;data=05%7C01%7CTAYLOR.DUPREE%40cuanschutz.edu%7Cf950887115d1468ab72408dbd406b6d5%7C563337caa517421aaae01aa5b414fd7f%7C0%7C0%7C638336897539204642%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=gKgwtEGxURMSzHzgxMbluPsKj1xmHvSyvlDuASUlQPw%3D&amp;reserved=0" target="_blank" rel="noopener noreferrer">https://covid.cd2h.org/cardiology</a> or email <a href="mailto:n3c-dt-cardiology@googlegroups.com">n3c-dt-cardiology@googlegroups.com</a>. &nbsp;

Not affiliated with any listed CTSA hubs

medium_N3C logo with text side by side.png

small_N3C logo with text side by side.png

thumbnail_N3C logo with text side by side.png

N3C logo with text side by side.png

National COVID Cohort Collaborative (N3C) Cardiovascular Disease Domain Team Makes Early Discoveries in Link Between COVID-19 and Cardiovascular Disease

X-logo-teal_80x66.png

ri_linkedin_fill_408497d4b5_96748f4451.png

Goal #3: Address health disparities 

SC CTSI's Community Engagement core group pioneers a model for trust and collaboration between academia and under-resourced communities. The initiative, based in Nickerson Gardens, addresses healthcare challenges identified through focused listening sessions.&nbsp;In addition to improving clinical care and health outcomes through cutting-edge research, the Southern California Clinical and Translational Science Institute (SC CTSI) is also committed to addressing the unique healthcare challenges faced by under-resourced communities…&nbsp;Read the full article <a href="https://sc-ctsi.org/news/sc-ctsis-town-hall-in-nickerson-gardens-serves-as-a-catalyst-for-community-collaboration-in-the-pursuit-of-health-equity" target="_blank" rel="noopener noreferrer">here</a>.

Southern California Clinical and Translational Science Institute

thumbnail_NG_TownHall-1.jpg

NG_TownHall-1.jpg

University of Southern California

SC CTSI's Town Hall in Nickerson Gardens Serves as a Catalyst for Community Collaboration in the Pursuit of Health Equity

CTSA CCOS

Home

About

CTSA Groups and Meetings

Resources

News

Help

CTSA News

Date

Share this News Post

ICTS Precision Health Team Develops Genomic Return of Results Service